Citation
Liu, Hui, et al. "Busulfan Plus Fludarabine as a Myeloablative Conditioning Regimen Compared With Busulfan Plus Cyclophosphamide for Acute Myeloid Leukemia in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Prospective and Multicenter Study." Journal of Hematology & Oncology, vol. 6, 2013, p. 15.
Liu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol. 2013;6:15.
Liu, H., Zhai, X., Song, Z., Sun, J., Xiao, Y., Nie, D., Zhang, Y., Huang, F., Zhou, H., Fan, Z., Tu, S., Li, Y., Guo, X., Yu, G., & Liu, Q. (2013). Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. Journal of Hematology & Oncology, 6, 15. https://doi.org/10.1186/1756-8722-6-15
Liu H, et al. Busulfan Plus Fludarabine as a Myeloablative Conditioning Regimen Compared With Busulfan Plus Cyclophosphamide for Acute Myeloid Leukemia in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Prospective and Multicenter Study. J Hematol Oncol. 2013 Feb 8;6:15. PubMed PMID: 23394705.
TY - JOUR
T1 - Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
AU - Liu,Hui,
AU - Zhai,Xiao,
AU - Song,Zhaoyang,
AU - Sun,Jing,
AU - Xiao,Yang,
AU - Nie,Danian,
AU - Zhang,Yu,
AU - Huang,Fen,
AU - Zhou,Hongsheng,
AU - Fan,Zhiping,
AU - Tu,Sanfang,
AU - Li,Yonghua,
AU - Guo,Xutao,
AU - Yu,Guopan,
AU - Liu,Qifa,
Y1 - 2013/02/08/
PY - 2012/12/02/received
PY - 2013/02/03/accepted
PY - 2013/2/12/entrez
PY - 2013/2/12/pubmed
PY - 2013/7/26/medline
SP - 15
EP - 15
JF - Journal of hematology & oncology
JO - J Hematol Oncol
VL - 6
N2 - OBJECTIVE: We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) in first complete remission (CR1). METHODS: Totally 108 AML-CR1 patients undergoing allo-HSCT were randomized into BuCy (busulfan 1.6 mg/kg, q12 hours, -7 ~ -4d; cyclophosphamide 60 mg/kg.d, -3 ~ -2d) or BuFlu (busulfan 1.6 mg/kg, q12 hours, -5 ~ -2d; fludarabine 30 mg/m2.d, -6 ~ -2d) group. Hematopoietic engraftment, regimen-related toxicity (RRT), graft-versus-host disease (GVHD), transplant related mortality (TRM), and overall survival were compared between the two groups. RESULTS: All patients achieved hematopoietic reconstitution except for two patients who died of RRT during conditioning. All patients obtained complete donor chimerism by day +30 post-transplantation. The incidence of total and III-IV RRT were 94.4% and 81.5% (P = 0.038), and 16.7% and 0.0% (P = 0.002), respectively, in BuCy and BuFlu group. With a median follow up of 609 (range, 3-2130) days after transplantation, the 5-year cumulative incidence of TRM were 18.8 ± 6.9% and 9.9 ± 6.3% (P = 0.104); the 5-year cumulative incidence of leukemia relapse were 16.5 ± 5.8% and 16.2 ± 5.3% (P = 0.943); the 5-year disease-free survival and overall survival were 67.4 ± 7.6% and 75.3 ± 7.2% (P = 0.315), and 72.3 ± 7.5% and 81.9 ± 7.0% (P = 0.177), respectively in BuCy and BuFlu group. CONCLUSION: Compared with BuCy, BuFlu as a myeloablative condition regimen was associated with lower toxicities and comparable anti-leukemic activity in AML-CR1 patients undergoing allo-HSCT.
SN - 1756-8722
UR - https://www.unboundmedicine.com/medline/citation/23394705/Busulfan_plus_fludarabine_as_a_myeloablative_conditioning_regimen_compared_with_busulfan_plus_cyclophosphamide_for_acute_myeloid_leukemia_in_first_complete_remission_undergoing_allogeneic_hematopoietic_stem_cell_transplantation:_a_prospective_and_multicenter_study_
L2 - https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-6-15
DB - PRIME
DP - Unbound Medicine
ER -